The OPDIVO+YERVOY combination therapy received accelerated approval from the F.D.A. for unresectable or metastatic melanoma regardless of a patient’s BRAF mutation. OPDIVO also received accelerated approval as a single therapy for previously untreated advanced melanoma patients with a BRAF positive mutation1.
Both OPDIVO and YERVOY are available from Onco360 Oncology Pharmacy. Order Now.
